Corcept Therapeutics’ Post

In this Diabetes Care publication, we take a deep-dive into CGM data from two once-weekly icodec trials to answer pertinent clinical questions. Specifically, the hypoglycemia results are highly reassuring, given the context that the ONWARDS 2 and 4 trials included people with longstanding type 2 diabetes switching from basal alone or basal-bolus regimen ie those who would be deemed to be at high risk for hypoglycemia. Here's the free link to the full publication https://lnkd.in/gpqzPUYB

How can individualized management strategies reduce long-term complications and improve outcomes in patients with type 2 diabetes? In this educational program, Drs. Jennifer Green and Tina Thethi explore the importance of tailoring type 2 diabetes treatment to individual patient needs, including key considerations for selecting incretin-based therapies and the impact of weight loss on glycemic control. Their discussion illuminates the importance of a holistic, patient-centric approach in diabetes care, emphasizing shared decision-making and the incorporation of lifestyle modifications alongside pharmacological interventions. They also examine the concept of therapeutic inertia and its impact on diabetes management, emphasizing the importance of regular, proactive regimen evaluations to prevent long-term complications. Explore the importance of personalized care in type 2 diabetes management: https://ow.ly/j1vh50QFK8x #PatientCenteredCare #IncretinTherapies #DiabetesManagement

How can individualized management strategies reduce long-term complications and improve outcomes in patients with type 2 diabetes? In this educational program, Drs. Jennifer Green and Tina Thethi explore the importance of tailoring type 2 diabetes treatment to individual patient needs, including key considerations for selecting incretin-based therapies and the impact of weight loss on glycemic control. Their discussion illuminates the importance of a holistic, patient-centric approach in diabetes care, emphasizing shared decision-making and the incorporation of lifestyle modifications alongside pharmacological interventions. They also examine the concept of therapeutic inertia and its impact on diabetes management, emphasizing the importance of regular, proactive regimen evaluations to prevent long-term complications. Explore the importance of personalized care in type 2 diabetes management: https://ow.ly/2nHT50QFK5P #PatientCenteredCare #IncretinTherapies #DiabetesManagement

When it comes to hypernatraemia: The Systematized Nomenclature of Medicine Clinical Terminology February 2024 edition renamed diabetes insipidus as arginine vasopressin-related polyuria with two specific subtypes: arginine vasopressin deficiency and arginine vasopressin resistance. One of the reasons for this was shown in a recent survey of 1034 patients with central Diabetes Insipidus (CDI), 823 (80%) patients encountered a situation where a healthcare professional confused CDI with diabetes mellitus, and 884 (85%) patients supported renaming the disease https://lnkd.in/eQw5_kif #Nephrohealth #Nephrohealth_KA

🩺 While more research is needed to fully understand the effects of red light therapy on diabetes, these preliminary results are promising. With further investigation, this non-invasive treatment could become a valuable tool in the fight against diabetes-related complications. #MedicalAdvancements #Healthcare 🌈 https://bit.ly/4c2zlMm

Unbundling Diabetes (Infographic): How technology is transforming the care and management of diabetes. These companies are reshaping diabetes treatment using advanced diagnostics and groundbreaking therapies. Image Source: CBInsight The article link is in the comment section. #Worlddiabetesday #Diabetes #Diabetesmanagement #WorldDiabetesDay2023  #digitalhealth

 Our first Institutional Insights video series is now available! "Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression," features insights from experts in diabetes management from Albany Medical Center who are using teplizumab with young patients to delay progression of type 1 diabetes from type 1 stage 2 to type 1 stage 3, or frank diabetes. They discuss type 1 diabetes screening, staging, and appropriate follow-up; explore the teplizumab mechanism of action; look at location options for infusion, and more.   https://lnkd.in/eiymhTgN

The goal of the TACT2 trial was to determine the potential clinical benefit of the chelating agent edetate disodium (EDTA) in older adults with a history of #cvMI and diabetes mellitus. Read the clinical trial details here: https://bit.ly/4aoYXBM #ACC24